Is Micron a Good Stock to Buy Now?
Like most of its peers in the semiconductor industry, Micron…
Sell
16
TRIB Quote, Financials, Valuation and Earnings
Last price:
$0.53
Seasonality move
:
7.94%
Day range:
$0.53 - $0.59
52-week range:
$0.48 - $3.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.10x
P/B ratio:
--
Volume:
37.8K
Avg. volume:
38.7K
1-year change:
-70.89%
Market cap:
$10.4M
Revenue:
$56.8M
EPS (TTM):
-$2.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
$16M | -$0.28 | 8.81% | -25.13% | -- |
|
AKTX
Akari Therapeutics PLC
|
-- | -- | -- | -- | -- |
|
AMRN
Amarin Corp PLC
|
$50.7M | -$0.40 | -28.71% | -- | $13.50 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
DBVT
DBV Technologies SA
|
$501.4K | -$0.24 | -- | -82.82% | $22.63 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
$0.54 | -- | $10.4M | -- | $0.00 | 0% | 0.10x |
|
AKTX
Akari Therapeutics PLC
|
$1.10 | -- | $27.2M | -- | $0.00 | 0% | -- |
|
AMRN
Amarin Corp PLC
|
$9.36 | $13.50 | $193.8M | -- | $0.00 | 0% | 0.84x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.46 | $17.97 | $3.7M | -- | $0.00 | 0% | 1.52x |
|
DBVT
DBV Technologies SA
|
$7.91 | $22.63 | $216.2M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.91 | $104.00 | $5.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
147.47% | -0.355 | 785.94% | 0.87x |
|
AKTX
Akari Therapeutics PLC
|
-- | -1.374 | -- | -- |
|
AMRN
Amarin Corp PLC
|
-- | 0.049 | -- | 2.31x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 1.825 | -- | 1.20x |
|
DBVT
DBV Technologies SA
|
-- | -2.465 | -- | -- |
|
NCNA
NuCana PLC
|
-- | 0.371 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TRIB
Trinity Biotech PLC
|
$5.3M | -$2.2M | -45.03% | -- | -11.29% | -$6.3M |
|
AKTX
Akari Therapeutics PLC
|
-- | -$1.9M | -- | -- | -- | -$1.5M |
|
AMRN
Amarin Corp PLC
|
-$9.6M | -$52.5M | -15.41% | -15.41% | -60.86% | -$13.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -$23.8M | -- | -- | -- | -$9.8M |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
Trinity Biotech PLC vs. Competitors
-
Which has Higher Returns TRIB or AKTX?
Akari Therapeutics PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat Akari Therapeutics PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M AKTXAkari Therapeutics PLC-- -$0.24 -- -
What do Analysts Say About TRIB or AKTX?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2677.78%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 7172.73%. Given that Akari Therapeutics PLC has higher upside potential than Trinity Biotech PLC, analysts believe Akari Therapeutics PLC is more attractive than Trinity Biotech PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 AKTXAkari Therapeutics PLC0 0 0 -
Is TRIB or AKTX More Risky?
Trinity Biotech PLC has a beta of 1.210, which suggesting that the stock is 20.986% more volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.51%.
-
Which is a Better Dividend Stock TRIB or AKTX?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or AKTX?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is lower than Akari Therapeutics PLC's net income of -$2.9M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.10x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.10x -- $15.2M -$4.8M AKTXAkari Therapeutics PLC-- -- -- -$2.9M
-
Which has Higher Returns TRIB or AMRN?
Amarin Corp PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of -78.03%. Trinity Biotech PLC's return on equity of -- beat Amarin Corp PLC's return on equity of -15.41%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M AMRNAmarin Corp PLC-15.36% -$0.12 $486.2M -
What do Analysts Say About TRIB or AMRN?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2677.78%. On the other hand Amarin Corp PLC has an analysts' consensus of $13.50 which suggests that it could grow by 44.23%. Given that Trinity Biotech PLC has higher upside potential than Amarin Corp PLC, analysts believe Trinity Biotech PLC is more attractive than Amarin Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 AMRNAmarin Corp PLC0 1 0 -
Is TRIB or AMRN More Risky?
Trinity Biotech PLC has a beta of 1.210, which suggesting that the stock is 20.986% more volatile than S&P 500. In comparison Amarin Corp PLC has a beta of 1.384, suggesting its more volatile than the S&P 500 by 38.378%.
-
Which is a Better Dividend Stock TRIB or AMRN?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Amarin Corp PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or AMRN?
Trinity Biotech PLC quarterly revenues are $15.2M, which are smaller than Amarin Corp PLC quarterly revenues of $62.3M. Trinity Biotech PLC's net income of -$4.8M is higher than Amarin Corp PLC's net income of -$48.6M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Amarin Corp PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.10x versus 0.84x for Amarin Corp PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.10x -- $15.2M -$4.8M AMRNAmarin Corp PLC0.84x -- $62.3M -$48.6M
-
Which has Higher Returns TRIB or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About TRIB or BDRX?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2677.78%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1139.15%. Given that Trinity Biotech PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Trinity Biotech PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is TRIB or BDRX More Risky?
Trinity Biotech PLC has a beta of 1.210, which suggesting that the stock is 20.986% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.705, suggesting its more volatile than the S&P 500 by 70.482%.
-
Which is a Better Dividend Stock TRIB or BDRX?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or BDRX?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.10x versus 1.52x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.10x -- $15.2M -$4.8M BDRXBiodexa Pharmaceuticals PLC1.52x -- -- --
-
Which has Higher Returns TRIB or DBVT?
DBV Technologies SA has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M DBVTDBV Technologies SA-- -$1.10 -- -
What do Analysts Say About TRIB or DBVT?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2677.78%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 185.08%. Given that Trinity Biotech PLC has higher upside potential than DBV Technologies SA, analysts believe Trinity Biotech PLC is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 DBVTDBV Technologies SA0 0 0 -
Is TRIB or DBVT More Risky?
Trinity Biotech PLC has a beta of 1.210, which suggesting that the stock is 20.986% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.
-
Which is a Better Dividend Stock TRIB or DBVT?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or DBVT?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than DBV Technologies SA quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is higher than DBV Technologies SA's net income of -$23M. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.10x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.10x -- $15.2M -$4.8M DBVTDBV Technologies SA-- -- -- -$23M
-
Which has Higher Returns TRIB or NCNA?
NuCana PLC has a net margin of -31.41% compared to Trinity Biotech PLC's net margin of --. Trinity Biotech PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About TRIB or NCNA?
Trinity Biotech PLC has a consensus price target of --, signalling upside risk potential of 2677.78%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 11366.37%. Given that NuCana PLC has higher upside potential than Trinity Biotech PLC, analysts believe NuCana PLC is more attractive than Trinity Biotech PLC.
Company Buy Ratings Hold Ratings Sell Ratings TRIBTrinity Biotech PLC0 0 0 NCNANuCana PLC0 1 0 -
Is TRIB or NCNA More Risky?
Trinity Biotech PLC has a beta of 1.210, which suggesting that the stock is 20.986% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.355%.
-
Which is a Better Dividend Stock TRIB or NCNA?
Trinity Biotech PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trinity Biotech PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRIB or NCNA?
Trinity Biotech PLC quarterly revenues are $15.2M, which are larger than NuCana PLC quarterly revenues of --. Trinity Biotech PLC's net income of -$4.8M is lower than NuCana PLC's net income of -$836.1K. Notably, Trinity Biotech PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trinity Biotech PLC is 0.10x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRIBTrinity Biotech PLC0.10x -- $15.2M -$4.8M NCNANuCana PLC-- -- -- -$836.1K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
How High Will MSTY Go By 2030?
YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 36x
Alerts
Buy
91
TORXF alert for Apr 17
Torex Gold Resources [TORXF] is down 2.15% over the past day.
Sell
25
BULZ alert for Apr 17
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 1.92% over the past day.
Sell
44
VIST alert for Apr 17
Vista Energy SAB de CV [VIST] is up 6.93% over the past day.
